Classification of molecular subtypes of high-grade serous ovarian cancer by MALDI-Imaging.
نویسندگان
چکیده
e17544 Background: High-grade serous ovarian cancer (HGSOC) can be separated by gene expression profiling into four molecular subtypes with clear correlation of the clinical outcome. However, these signatures have not been implemented in practice to stratify patients for targeted therapy. This is mainly due a lack easy, cost-effective and reproducible methods, as well high heterogeneity HGSOC. Hence, we aimed examine potential unsupervised matrix assisted laser desorption/ionization imaging mass spectrometry (MALDI-IMS) patients, which might benefit from therapeutic strategies. Methods: Molecular subtyping paraffin-embedded tissue samples 279 HGSOC was performed NanoString analysis (ground truth labeling). Next, applied MALDI-IMS, novel technology identify distinct profiles on same sections paired machine learning algorithms proteomic signature. Finally, devised strategy annotate spectra stromal origin. Results: We elucidated MALDI-derived signature (135 peptides) able classify subtypes. Random forest classifiers achieved an area under curve (AUC) 0.983. Furthermore, demonstrated that exclusion stroma associated provides tangible improvements classification quality (AUC = 0.988). False discovery rates (FDR) were reduced 10.2% 8.0%. MALDI-based annotation near-perfect classifications 0.999, FDR < 1.0%). Conclusions: Here, present concept integrating MALDI-IMS according has great assign therapies.
منابع مشابه
Molecular Abnormalities in Ovarian Cancer Subtypes Other than High-Grade Serous Carcinoma
Ovarian cancer is the fifth leading cause of cancer death in women in North America, and approximately two-thirds of cases of ovarian cancer are of high-grade serous type. The remaining cases are comprised of a mix of different tumor types (e.g., endometrioid, clear cell, mucinous, etc.), with no single tumor type accounting for more than 10% of ovarian cancer cases. These tumor types can be re...
متن کاملA clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression
To establish an effective hormone receptor-based molecular classification of high-grade serous ovarian cancer (HGSC), we retrospectively examined 875 consecutive HGSC patients who underwent primary surgery at our hospital and constructed tissue microarrays from these specimens. The expression levels of the hormone receptors were as follows: ER 64.4%, PR 12.6%, AR 35.6%, FSHR 54.5%, LHR 34.8%, a...
متن کاملComprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three Subtypes
Four gene expression subtypes of high-grade serous ovarian cancer (HGSC) have been previously described. In these early studies, a fraction of samples that did not fit well into the four subtype classifications were excluded. Therefore, we sought to systematically determine the concordance of transcriptomic HGSC subtypes across populations without removing any samples. We created a bioinformati...
متن کاملOrigin and molecular pathogenesis of ovarian high-grade serous carcinoma.
A new paradigm for the pathogenesis of ovarian cancer has recently been proposed which helps to explain persistent problems in describing the development and diverse morphology of these neoplasms. The paradigm incorporates recent advances in our understanding of the molecular pathogenesis of epithelial 'ovarian' cancer with new insights into the origin of these tumors. Correlated clinicopatholo...
متن کاملHigh-Grade Serous Ovarian Cancers
The fallopian tube is now generally considered the dominant site of origin for high-grade serous ovarian carcinoma. However, the molecular pathogenesis of fallopian tube-derived serous carcinomas is poorly understood and there are few experimental studies examining the transformation of human fallopian tube cells. Prompted by recent genomic analyses that identified cyclin E1 (CCNE1) gene amplif...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Oncology
سال: 2021
ISSN: ['1527-7755', '0732-183X']
DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.e17544